Key facts
- This page summarizes Robert A. Lenz's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
- 4 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 18 Feb 2025, 16:30.
Robert A. Lenz - 13 Feb 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)
- Reporting relationship
- Head of R&D
- Issuer ticker
- NMRA
- Reported as of
- 13 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Feb 2025, 16:30:08 UTC
- Prior SEC filing
- 11 Oct 2024
- Next SEC filing
- 20 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Milligan, as Attorney-in-Fact for Robert A. Lenz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert A. Lenz filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 18 Feb 2025.
Change
- Previous filing in this sequence was filed on 11 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NMRA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -502,934
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 502,934
- Exercise price
- $17.00
- Footnotes
- F1, F2
NMRA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -100,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $18.07
- Footnotes
- F2, F3
NMRA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +502,934
- Change %
- Price
- Shares after
- 502,934
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 502,934
- Exercise price
- $1.69
- Footnotes
- F1, F2, F4
NMRA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +100,000
- Change %
- Price
- Shares after
- 100,000
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.69
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
25% of the shares subject to the option vest on the first anniversary measured from September 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Footnote F2
On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
Footnote F3
25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Footnote F4
Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.